Tree Accountancy strengthens its regional footprint by absorbing Pomegranate Consulting's UK portfolio and key staff, marking its second strategic acquisition in three years as it expands advisory services.
Turkish energy firm Reges Elektrik has completed its acquisition of Tuşpa Enerji, unlocking the start of operations at the 70MW Demirli Wind Power Project in Kırşehir and marking its strategic shift into large-scale power generation.
Hawxhurst LLP has filed a federal lawsuit against International Amusement Rides and Intamin Ltd., alleging the roller coaster manufacturers failed to pay $1.5 million in legal fees after the firm defended them in high-stakes intellectual property battles.
As Kevin Warsh emerges as a frontrunner for Federal Reserve Chair, former colleagues paint a picture of a consensus-seeking listener. But with the Fed facing internal divisions and external pressure, questions remain: Is his collaborative style the steady hand needed, or a potential liability in times of crisis?
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Despite posting strong quarterly results and outperforming major indices over the past year, U.S. Bancorp's stock is met with a measured 'Moderate Buy' consensus from analysts, highlighting a divergence between performance and sentiment.
The parent company of Fatburger and Round Table Pizza, along with its Twin Hospitality spinoff, will be removed from the Nasdaq exchange effective February 4, transitioning to the over-the-counter market following Chapter 11 filings and over $1 billion in debt.
The Schwab U.S. Dividend Equity ETF (SCHD) offers investors a balanced approach to generating income, targeting financially robust companies with a history of growing dividends. We examine its strategy, performance, and role in a portfolio.
As economic pressures mount, flexible remote work opportunities are evolving. We examine four proven side gigs that experts project can still generate significant weekly earnings from home in the coming years.
Freedom Capital initiates coverage on Mama's Creations (MAMA) with a Buy rating and a $16 price target, citing the company's expanding national footprint, product innovation, and strong recent earnings as key growth catalysts in the fresh meal sector.
In a joint diplomatic push, Chile, Brazil, and Mexico have officially submitted former Chilean President Michelle Bachelet's candidacy to become the first woman to lead the United Nations, as the race to succeed Antonio Guterres heats up.
FreightTech innovator GenLogs has closed a $60 million Series B round led by Battery Ventures. The startup, founded by a former CIA officer, leverages a vast sensor network and AI to bring unprecedented visibility and security to the fragmented trucking industry.
The Vatican has launched a meticulous three-month restoration of Michelangelo's iconic 'Last Judgment' fresco in the Sistine Chapel, aiming to revive the masterpiece's original chromatic brilliance obscured by decades of grime.
Despite a recent sales miss, AutoZone (AZO) is doubling down on store growth, drawing mixed analyst reactions. JPMorgan remains bullish with an $4,100 price target, while Wolfe Research downgraded the stock, highlighting the complex landscape for the auto parts retailer.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
